Collective Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Collective Family Office’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-256	Closed	-$225K	–	182
2023 Q4	$225K	Sell	256 -99	-28%	-$81.5K	0.08%	157
2023 Q3	$292K	Buy	355 +50	+16%	+$39.3K	0.11%	135
2023 Q2	$219K	Buy	+305	New	+$235K	0.09%	164
2022 Q3	–	Sell	-476	Closed	-$281K	–	194
2022 Q2	$281K	Buy	476 +172	+57%	+$112K	0.12%	154
2022 Q1	$212K	Sell	304 -155	-34%	-$98.1K	0.08%	182
2021 Q4	$290K	Sell	459 -19	-4%	-$11.7K	0.11%	153
2021 Q3	$289K	Sell	478 -3	-0.6%	-$1.86K	0.12%	141
2021 Q2	$269K	Sell	481 -75	-13%	-$38K	0.12%	147
2021 Q1	$263K	Buy	+556	New	+$271K	0.13%	144

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Collective Family Office's REGN Position: Q1 2024 in Review

Collective Family Office sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 256 shares — an estimated $225K sold.

Collective Family Office first reported a position in REGN in Q1 2021 and held it in 9 quarters. The position peaked at $292K in Q3 2023. 1,312 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Collective Family Office reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Collective Family Office sold 256 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $225K.
Collective Family Office first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 9 quarters.
Collective Family Office's Regeneron Pharmaceuticals position peaked at $292K in Q3 2023.
1,312 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Collective Family Office's 13F filing for Q1 2024, filed 9 Apr 2024.